Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul-Sep;19(2):184-193.
doi: 10.22074/cellj.2016.4251. Epub 2017 Feb 22.

Radioactive Iodine Therapy and Glucose Tolerance

Roghaieh Samadi  1 , Babak Shafiei  2 , Fereidoun Azizi  3 , Asghar Ghasemi  1
Affiliations
Review

Radioactive Iodine Therapy and Glucose Tolerance

Roghaieh Samadi et al. Cell J. 2017 Jul-Sep.

Abstract

Radioactive iodine therapy is commonly used as an adjuvant therapy in follicular and papillary thyroid carcinoma (PTC) and in the treatment of Graves' disease (GD). The basis of this therapy is the accumulation of radioactive iodine by the sodium-iodide symporter (NIS) in the thyroid gland. Expression of NIS by extrathyroidal tissues such as islets of pancreas has been reported. Radioactive iodine uptake by pancreatic beta-cells can potentially damage these cells. In this study, we discuss the possible associations between radioactive iodine and glucose intolerance. Overall, radioactive iodine uptake by the pancreas may damage beta-cells and predispose patients to glucose intolerance or type 2 diabetes, particularly in patients exposed to radioactive iodine therapy following total thyroidectomy. Further studies are needed to clarify and confirm this association.

Keywords: Glucose Tolerance; Iodine; Pancreas; Radioactive; Sodium-Iodide Symporter.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Glucose enters beta-cells through glucose transporter 2 (GLUT2) and converts to pyruvate in the glycolysis pathway. Pyruvate enters the mitochondrion to be metabolized further and produce ATP. An increased ATP/ADP ratio is necessary for insulin secretion. I-131 (radioactive iodine) enters beta-cells via the sodium-iodide symporter (NIS) and produces reactive oxygen species (ROS). Increased ROS in beta-cells activates uncoupling protein-2 (UCP-2) that decreases the ATP/ADP ratio, leading to suppressed glucose-stimulated insulin secretion (GSIS). Directly, beta-particles interact with essential molecules and disrupt DNA, while indirectly, beta-particles produce ROS by partial reduction of oxygen (O2) and interaction with water molecules. Increased ROS in the nucleus decreases pancreatic duodenal homeobox-1 (PDX-1) expression and activity, and decreases insulin gene expression. TCA; Tricarboxylic acid and VDCC; Voltage-dependent calcium channel.
See this image and copyright information in PMC

References

    1. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7(2):163–176. - PubMed
    1. Rivkees SA, Dinauer C. The use of 131 iodine in the treatment of Graves’ disease in children. In: Preedy VR, Burrow GN, Watson R, editors. Comprehensive handbook of iodine: nutritional, biochemical, pathological and therapeutic aspects. 1st ed. Boston: Academic Press; 2009. pp. 943–992.
    1. Gittoes NJ, Franklyn JA. Hyperthyroidism.Current treatment guidelines. Drugs. 1998;55(4):543–553. - PubMed
    1. Fernandes JK, Day TA, Richardson MS, Sharma AK. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol. 2005;6(1):47–57. - PubMed
    1. Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva- O'Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42(5):738–743. - PubMed

LinkOut - more resources